Mullins and Mullins. Perspective Series: Molecular Medicine in Genetically Engineered Animals. Apr. 1, 1996. Clinical Investigation. vol. 97, No. 7, pp. 1557-1560.* |
Sigmund. Viewpoint: Are Studies in Genetically Altered mice Out of Control? Jun., 2000. Arterioscler Thromb. Vasc. Biol. vol. 20. pp. 1425-1429.* |
Wall. Transgenic Livestock: Progress and Prospects for the Future. 1996. Theriogenology. vol. 45, pp. 57-68.* |
Ross et al. Phenotypic characterization of an alpha 4 neuronal nicotine acetylcholine receptor subunit knock out mouse. The Journal of Neuroscience, Sep. 1, 2000. vol. 20, No. 17, pp. 6431-6441.* |
Campbell and Wilmut. Totipotency or Multipotentiality of Cultured Cells: Applications and Progress. Theriogenology. Jan. 1, 1997. vol. 47, No. 1, pp. 63-70.* |
Jacks et al. Effects of an Rb mutation in the mouse. Sep. 24, 1992.Nature. vol. 359, pp. 295-300.* |
Bradley et al. Modifying the Mouse: Design and Desire. May 1992. Biotechnology. vol. 10, pp. 534-539.* |
Labarca et al., “Point mutant mice with hypersensitive α4 nicotinic receptors show dopaminergic deficits and increased anxiety,” PNAS, vol. 98, No. 5, Feb. 27, 2001, pp. 2786-2791. |
Labarca et al., “Knockin mice with hypersensitive neuronal nicotinic receptors,” Society for Neuroscience Abstracts, vol. 26, No. 1-2 (2000). |
Cordero-Erausquin et al., “Nicotinic receptor function: new perspectives from knockout mice,” Elsevier Science Ltd., vol. 21, Jun. 2000, pp. 211-217. |
Orr-Urtreger et al., “Mice Homozygous for the L250T Mutation in the α7 Nicotinic Acetylcholine Receptor Show Increased Neuronal Apoptosis and Die Within 1 Day of Birth,” Jorunal of Neurochemistry, vol. 74, No. 5, 2000. |
Marubio et al., “Reduced antinociception in mice lacking neuronal nicotinic receptor subunits,” Nature, vol. 398, Apr. 29, 1999, pp 805-810. |
Labarca et al., “Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors,” Nature, vol. 376, Aug. 10, 1995. |
Decker et al., “(S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl)Isoxazole (ABT 418): A Novel Cholinergic Ligand with Cognition-Enhancing and Anxiolytic Activities: II. In Vivo Characterization,” The Journal of Pharmacology and Experimental Therapeutics, vol. 270, No. 1, 1994, pp. 319-328. |